2015
DOI: 10.1002/mc.22410
|View full text |Cite
|
Sign up to set email alerts
|

Different induction of LPA receptors by chemical liver carcinogens regulates cellular functions of liver epithelial WB‐F344 cells

Abstract: Lysophosphatidic acid (LPA) signaling via LPA receptors (LPA to LPA ) mediates a variety of cellular functions, including cell motility. In the present study, we investigated the effects of LPA receptors on cell motile activity during multi-stage hepatocarcinogenesis in rat liver epithelial WB-F344 cells treated with chemical liver carcinogens. Cells were treated with a initiator (N-nitrosodiethylamine (DEN)) and three promoters (phenobarbital (PB), okadaic acid (OA) and clofibrate) every 24 h for 2 days. Cell… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2017
2017
2018
2018

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 8 publications
(1 citation statement)
references
References 36 publications
(74 reference statements)
0
1
0
Order By: Relevance
“…ONO-8430506, a tetrahydrocarboline derivative and ATX inhibitor, has been used to suppress plasma ATX activity in mice [110]. In another study, S32826, a benzyl phosphonic acid derivative ATX inhibitor, was used to reduce chemical liver carcinogenesis [111]. In other studies, a-bromophosphonates (BrP-LPA), which are lipid-mimetic ATX inhibitors and pan-antagonists of LPA1-3 receptors, were used to reduce breast tumor growth in orthotopic xenograft models [112] and lung cancer metastasis in nude mice [113].…”
Section: Development Of Inhibitors Against the Atx-lpa Signaling Axismentioning
confidence: 99%
“…ONO-8430506, a tetrahydrocarboline derivative and ATX inhibitor, has been used to suppress plasma ATX activity in mice [110]. In another study, S32826, a benzyl phosphonic acid derivative ATX inhibitor, was used to reduce chemical liver carcinogenesis [111]. In other studies, a-bromophosphonates (BrP-LPA), which are lipid-mimetic ATX inhibitors and pan-antagonists of LPA1-3 receptors, were used to reduce breast tumor growth in orthotopic xenograft models [112] and lung cancer metastasis in nude mice [113].…”
Section: Development Of Inhibitors Against the Atx-lpa Signaling Axismentioning
confidence: 99%